Table 1 Characteristics of the disease in the 10 patients with Parkinson's disease.
Characteristic | Patient | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ||||||||
Duration of disease (years) | 18 | 10 | 10 | 29 | 13 | 19 | 6 | 12 | 8 | 12 | |||||||
Hoehn–Yahr stage | III | III | III | IV | III | III | III | IV | III | IV | |||||||
UPDRS part III in the on state | 30 | 19 | 28 | 33 | 22 | 24 | 31 | 35 | 25 | 31 | |||||||
UPDRS part III in the off state | 45 | 57 | 40 | 65 | 38 | NA | 40 | 48 | 44 | 44 | |||||||
Levodopa (mg/day); duration (years) | 1750; 14 | 1000; 8 | 1000; 8 | 2200; 25 | 850; 12 | 800; 18 | 400; 5 | 1350; 10 | 1200; 8 | 600; 10 | |||||||
Other drugs, mg/day | Bromocriptin 15 | Pergolide 6; Amantadine 300 | Bromocriptin 40; Amantadine 300 | Pergolide 3; Amantadine 300 | Piribedil 100; Segiline 10 | Bromocriptin 50; Segiline 10 | None | Trihexipphenidyle 4 | Lisuride 0.8; Segiline 10 | Bromocriptin 15; Trihexipphenidyle 10; Tolcapone 600 |
UPDRS, Unified Parkinson's Disease Rating Scale.